Apnea

Search documents
L'Apnea come metafora della vita | Chiara Obino | TEDxCagliari
TEDx Talks· 2025-07-09 14:55
5 4 3 two one official top 20. L'apnea è essenza, è viaggiare leggeri e in effetti non servono tante cose per sopravvivere laggiù. Abbandonare il superfluo rende più lucida la mente e più leggero il carico.Non si tratta di essere solo presenti a se stessi, ma di essere totalmente centrati rispetto ai veri bisogni. Sai che devi affrontare ogni sfida esattamente nel momento in cui si pone. Non puoi rimandare, ma non puoi farti prendere dall'ansia di risolvere.Impari a scegliere con cura cosa e come farlo, ad ...
RingConn智能戒指,全球首款支持睡眠呼吸暂停监测的智能戒指
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-07-09 05:19
在当今快节奏的生活中,睡眠问题逐渐成为困扰许多人的健康隐患。其中,阻塞性睡眠呼吸暂停(Obstructive Sleep Apnea,OSA)作为一种常见的睡眠呼吸 障碍,正悄然影响着无数人的健康。而如今,全球首款支持睡眠呼吸暂停监测的智能戒指——RingConn智能戒指的出现,为这一问题带来了突破性的解决 方案。 睡眠呼吸暂停:高患病率与低诊断率的矛盾现状 阻塞性睡眠呼吸暂停(OSA)是指睡眠过程中上气道反复塌陷阻塞,导致气流受限或完全阻断的睡眠呼吸障碍疾病,主要症状有打鼾、白天嗜睡、注意力不 集中等。它可能损害心血管和代谢系统,是高血压、冠心病、中风等多种高风险慢性疾病的独立危险因素。阻塞性睡眠呼吸暂停低通气综合征(OSAHS) 作为常见且严重的同类疾病,也会影响患者睡眠质量。据了解,25%的打鼾者伴有OSAHS,10%的OSAHS患者可能发展为高血压、中风、认知功能障碍等 疾病。 研究数据显示,OSA的患病率在总体人群中约占3%-7%,成人中占6%-17%,男性比例明显高于女性。全球30-69岁人群中,以睡眠呼吸暂停低通气指数≥5 次/小时为诊断标准,有约9.36亿人患有OSA,其中中重度患者约4.25 ...
Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance
Globenewswire· 2025-07-01 12:30
Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance TreatmentLITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced that its VidaSleep™ oral appliance, featuring Vivos’ patented and U.S. Food and Drug Administration (FD ...
New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children
Globenewswire· 2025-06-26 12:30
Important Study Shows Vivos Technology to be a Safe and Highly Effective, Non-Surgical Alternative to Surgical Removal of Tonsils and Adenoids in ChildrenLITTLETON, Colo., June 26, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive resul ...
Inspire Medical Systems (INSP) 2025 Conference Transcript
2025-06-13 17:02
Summary of Inspire Medical Systems (INSP) 2025 Conference Call Company Overview - **Company**: Inspire Medical Systems (INSP) - **Event**: 2025 Conference Call - **Date**: June 13, 2025 Key Points Industry and Market Dynamics - Discussion focused on the **Obstructive Sleep Apnea (OSA)** market and the competitive landscape surrounding it [2][10] - Emphasis on the **Inspire five** launch and its implications for the OSA treatment market [2][10] Inspire Five Launch - **Inspire five** features a **20% reduction in implant time** and improved sensing technology integrated into the neurostimulator [10][26] - The new device incorporates an **accelerometer** for respiration sensing, eliminating the need for a separate pressure sensing lead, thus simplifying the implant procedure [14][21] - The device allows for **Bluetooth communication** with a patient app and integrates with **SleepSync**, a cloud-based patient management system [11][12] Clinical Data and Performance - Clinical trials showed that **Inspire five** improved **inspiratory phase overlap** from **78% to 83%**, enhancing treatment effectiveness [22][24] - A study in Singapore indicated that the average nightly usage post-implant was **six hours**, demonstrating strong patient adherence [27] - The **St. Luke's Health** study reported over **80% success rate** in positional sleep apnea, indicating improved efficacy compared to previous trials [31][32] Surgeon Feedback and Adoption - Surgeons reported positive feedback regarding the ease of implantation without the pressure sensing lead, leading to reduced operating room (OR) time [41][42] - The transition to **Inspire five** is expected to increase the number of procedures performed by surgeons due to improved efficiency [64][70] Financial and Market Outlook - The company anticipates continued growth in adoption of Inspire therapy, with a focus on penetrating the **single-digit percentage** of the overall target market [38][39] - The **2025 guidance** includes expectations for increased capacity and productivity from surgeons, despite some anticipated competitive trials [82][83] Competitive Landscape - The emergence of **GLP-1 medications** for weight management in sleep apnea patients was discussed, with the potential for these treatments to complement Inspire therapy [98][104] - The company is monitoring the impact of GLP-1 on patient demand and treatment eligibility, noting that Inspire therapy remains effective for patients with tongue-based obstruction [100][103] Future Developments - Inspire is already working on **Inspire six**, which aims to enhance therapy adherence by detecting sleep states and automatically adjusting stimulation [90][91] - The integration of **SleepSync** with Inspire five is expected to facilitate better patient management and data collection for future improvements [92] Conclusion - Inspire Medical Systems is positioned for growth with the launch of Inspire five, leveraging advanced technology to improve patient outcomes and streamline surgical procedures. The company is optimistic about its market penetration and future innovations while navigating competitive pressures from emerging therapies.
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Globenewswire· 2025-06-11 12:30
Over $11 million in new financing secured by Vivos, including a senior secured loan from Streeterville Capital and an equity private placement by existing investor New Seneca Partners LITTLETON, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leader in delivering and promoting sleep wellness and health through its proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced the closing of its acquisition of the operati ...
Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program
Globenewswire· 2025-06-03 11:30
NEW YORK and MELBOURNE, Australia, June 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today announced the recent appointment of four distinguished experts to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board: Scott A. Sands, Ph.D., Associate Professor of Medicine at Harvard Medical School and Director of the Sleep Apnea Translational Physi ...
Nyxoah to Present at the Jefferies Global Healthcare Conference
Globenewswire· 2025-05-28 20:30
Company Overview - Nyxoah is a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA) [4] - The company's lead product is the Genio® system, which is a leadless and battery-free hypoglossal neurostimulation therapy for OSA [4] Recent Developments - Nyxoah will participate in the Jefferies Global Healthcare Conference from June 3 to June 5, 2025, in New York [2] - CEO Olivier Taelman will present on June 4, 2025, at 4:55 PM ET, with a webcast available on the company's Investor Relations website [3] - The company will also hold one-on-one meetings with institutional investors during the conference [3] Product Milestones - The Genio® system received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [5] - Nyxoah has completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021 [5] - The company received CE mark approval for expanded therapeutic indications to treat Complete Concentric Collapse (CCC) patients, which are currently contraindicated in competitors' therapies [5] - Positive outcomes from the DREAM IDE pivotal study have also been announced [5]
Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates
GlobeNewswire News Room· 2025-05-15 12:00
Core Viewpoint - Incannex Healthcare Inc. is making significant progress in its IHL-42X development program for treating obstructive sleep apnea (OSA), with key milestones expected in the near future [2]. Operational Highlights - The company secured $12.5 million in private placement funding to support the ongoing IHL-42X Phase 2/3 clinical program [7]. - An OSA Clinical Advisory Board was formed, with Dr. Alison Wimms appointed to enhance collaboration and clinical development efforts [7]. - More than 120 patients have been dosed across 11 clinical trial sites in the Phase 2 portion of the RePOSA study [7]. Clinical Highlights - IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide, currently in the RePOSA Phase 2/3 clinical trial, which aims to enroll over 560 patients globally [6]. - The trial is evaluating two doses of IHL-42X compared to placebo over a four-week treatment period, with topline data expected in July 2025 [7][8]. - Positive topline results from a pharmacokinetics and safety study confirmed the bioavailability of both active components in IHL-42X [7]. Financial Results - General and Administrative (G&A) expenses for the three months ended March 31, 2025, were $2.27 million, down from $4.14 million in the same period of 2024 [7]. - Research and Development (R&D) expenses for the same period totaled $2.74 million, compared to $3.28 million in 2024 [7]. - The net loss for the three-month period ended March 31, 2025, was $3.97 million, a decrease from $6.03 million in the prior year [7].
Nyxoah Reports First Quarter Financial and Operating Results
GlobeNewswire News Room· 2025-05-14 05:00
Core Insights - Nyxoah is on track for anticipated PMA approval of its Genio® system in the second quarter of 2025, having successfully completed FDA validation requirements and currently undergoing final site inspection [2][4][17] - The company reported a revenue of €1.1 million for Q1 2025, a decrease from €1.2 million in Q1 2024, with a gross profit margin of 61.8% [5][10][11] - Significant increases in research and development expenses (€9.0 million) and selling, general and administrative expenses (€12.4 million) were noted, contributing to an operating loss of €20.6 million for Q1 2025 [12][13][14] Financial Performance - Revenue for Q1 2025 was €1.1 million, down from €1.2 million in Q1 2024 [10] - Cost of goods sold was €406,000, resulting in a gross profit of €658,000 [11] - Research and development expenses rose to €9.0 million from €7.2 million year-over-year [12] - Selling, general and administrative expenses increased to €12.4 million from €6.0 million year-over-year [13] - The operating loss for Q1 2025 was €20.6 million, compared to €12.2 million in Q1 2024 [14] Cash Position - As of March 31, 2025, cash, cash equivalents, and financial assets totaled €63.0 million, down from €85.6 million at the end of 2024 [15] Regulatory Progress - The FDA issued an Approvable Letter for Nyxoah's PMA application for the Genio® system, indicating that the application meets the necessary requirements [6][17] - The final step before full PMA approval is an on-site inspection of the U.S. manufacturing site, which has already passed a previous inspection with no deficiencies [4][18] Company Overview - Nyxoah focuses on developing innovative solutions for Obstructive Sleep Apnea (OSA), with its lead product being the Genio® system, a hypoglossal neurostimulation therapy [21] - The company received its European CE Mark for the Genio® system in 2019 and has conducted successful IPOs on Euronext Brussels and NASDAQ [22]